sch-22219 and clobetasone-butyrate

Atopic dermatitis is commonly colonized with Staphylococcus aureus in high densities.. Our purpose was to study the effect of topical corticosteroids on the colonization of S. aureus in atopic dermatitis.. Sixty-six patients were treated with moderately potent, or very potent corticosteroids. Quantification of S. aureus and evaluation of the severity of the eczema was performed before, after 1 week, and after 2 weeks of treatment.. Fifty-three patients carried S. aureus in the most pronounced lesion before treatment. The colonization was significantly correlated with the severity of the eczema. The density of S. aureus was reduced by topical corticosteroids. The reduction increased with the potency of the corticosteroid and was most pronounced during the first week. S. aureus was eliminated after a successful 2-week treatment with a very potent corticosteroid. Propylene glycol 25% added to a moderately potent corticosteroid did not significantly increase the reduction of S. aureus.. Topical corticosteroids of sufficient potency reduce the density of S. aureus in atopic dermatitis.

Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Child; Child, Preschool; Clobetasol; Dermatitis, Atopic; Drug Therapy, Combination; Female; Humans; Male; Methylprednisolone; Middle Aged; Neomycin; Staphylococcal Infections; Staphylococcus aureus

A randomized, double-blind, parallel-group study was conducted comparing the efficacy and safety of alclometasone dipropionate cream 0.05% and clobetasone butyrate cream 0.05% in the treatment of atopic dermatitis in 43 children. The medications were applied to study areas as a thin layer of cream twice daily for 2 weeks. Efficacy was assessed by evaluation of three disease signs (erythema, induration, and pruritus) and by mean of a physician's global evaluation following treatment. Safety was evaluated through patient-reported and clinically observed adverse experiences. Both treatments were effective. At the end of the trial, average reduction in disease signs was 85% for alclometasone dipropionate-treated patients and 86% in the clobetasone butyrate-treated group. In the global evaluation, the physician rated symptoms as cleared in 9 of 22 alclometasone dipropionate-treated patients and in 10 of 21 clobetasone butyrate-treated patients.

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Clinical Trials as Topic; Clobetasol; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Male; Methylprednisolone

In a parallel group design, and using a 'blind evaluator' technique, alclometasone cream 0.05% and clobetasone butyrate cream 0.5% applied twice a day for 21 days were compared in thirty-one patients presenting with psoriasis. Erythema, induration and scaling were assessed at the start of treatment. Seven, 14 and 21 days later, effects of the two treatments were assessed and recorded together with the physician's global evaluation of overall improvement. Both drugs had similar beneficial effects on the clinical signs. No adverse experience was reported and the overall results indicate that alclometasone and clobetasone have comparable efficacy and safety.

Topics: Adult; Anti-Inflammatory Agents; Betamethasone; Clobetasol; Drug Evaluation; Humans; Methylprednisolone; Psoriasis